RxDoctor Payments Data

Pranjal Jain, MD

Nephrology · Temple Terrace, FLNPI 1730408121

Payments from drug & device makers

$4,701in general payments, 2019–2025

Across 104 payments — averaging $45.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baxter Healthcare$1K
  • AstraZeneca$339
  • Amgen$315
  • One Lambda, Inc.$297
  • Mallinckrodt Hospital Products Inc.$253
  • Outset Medical Inc$244
  • plus $2K from 22 others

What the payments were for

  • Travel & lodging$85518%
  • Food & beverage$3,82581%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,701 in reported general payments places this provider in the 65th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$206,904
Medicare patients
574
Services billed
2,009

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol127$120,996
OzempicSemaglutide61$58,761
Valganciclovir Hcl78$24,414
Envarsus XrTacrolimus27$16,484
LokelmaSodium Zirconium Cyclosilicate35$14,621
JardianceEmpagliflozin15$8,587
Cinacalcet Hcl27$6,658
Mycophenolate Mofetil19$1,768
Nifedipine ErNifedipine71$1,411
Tacrolimus22$1,400
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim287$1,287
Prednisone184$1,155
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$1,099
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic11$882
Bumetanide45$693

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$339$135,617162 claims
Novo NordiskOzempic$172$58,76161 claims
Boehringer IngelheimJardiance$45$8,58715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 756 nephrology providers in Florida.

Other nephrology in Temple Terrace

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →